Theme: medicines_regulation
Responsible: South African Health Products Regulatory Authority / Department of Health / Department of International Relations
High feasibility for SAHPRA-specific reforms within existing legislative mandate. AMA integration pathway is longer-term and depends on AU member state buy-in. Key constraint: SAHPRA budget adequacy and staff retention in competition with private pharma industry.
The African Medicines Agency (AMA) was established under the African Union framework and opened its headquarters in Yaoundé, Cameroon in 2021 after South Africa ratified the AMA Treaty. SAHPRA (South African Health Products Regulatory Authority) — one of Africa's most technically sophisticated medicines regulators — is positioned as a reference regulatory authority for the AMA framework, able to provide registration reliance mechanisms that allow other African countries to benefit from SAHPRA's rigorous reviews. SAHPRA's 2025-2030 Strategic Plan and 2025/26 Annual Performance Plan outline priorities including: implementing a fully risk-based assessment approach, reducing registration backlogs (critical for NHI benefit package design), strengthening post-market surveillance, and combating the proliferation of counterfeit pharmaceuticals and medical devices. On 30 September 2025, South Africa launched a National Action Plan on Substandard and Falsified Medical Products in partnership with WHO. SAHPRA is also refining its eCTD dossier submission standards and labelling requirements to align with international ICH guidelines, critical for attracting pharmaceutical manufacturers to register in South Africa as a gateway to African markets. The AMA-SAHPRA relationship represents South Africa's most concrete contribution to African health system integration under the AU Agenda 2063 framework.
South Africa's ratification of the AMA Treaty and SAHPRA's position as a reference regulatory authority creates the institutional architecture for safe, accessible medicines across Africa — but SAHPRA needs sustained investment to fulfil this role. — SAHPRA Strategic Plan 2025-2030
South Africa has ratified the AMA Treaty and SAHPRA is positioned as the continent's lead reference regulatory authority. The implementation agenda focuses on: (1) clearing SAHPRA's registration backlog through risk-stratified review lanes (critical for NHI benefit package design); (2) operationalising AMA reliance mechanisms that allow other African countries to rely on SAHPRA reviews, reducing continental regulatory duplication; and (3) combating the proliferation of substandard and falsified medicines under the September 2025 National Action Plan.
SAHPRA backlog clearance programme: implement risk-stratified review lanes — expedited for essential medicines and NHI benefit package medicines (target 90 days), standard for generics, enhanced review for novel biologicals and advanced therapy medicinal products
Operationalise AMA reliance mechanism: develop a standard SAHPRA assessment package format compatible with AMA harmonised dossier requirements; onboard 5 African countries as initial reliance partners (Ghana, Kenya, Tanzania, Zimbabwe, Botswana)
Implement WHO Collaborative Registration Procedure (CRP): fast-track registration of all WHO-prequalified medicines to a maximum of 90 days (current average is 18 months) through a ministerial regulatory amendment
National Reading and Literacy Crisis Response Programme
TVET College Quality and Industry Relevance — Artisan Pipeline
Primary Healthcare Platform Strengthening and CHW Integration
STEM Teacher Development and Retention Programme
Critical Skills List Update and Visa Fast-Track
How to cite
Wilse-Samson, L. (2026). African Medicines Agency Treaty Ratification and SAHPRA Strengthening. SA Policy Space. NYU Wagner School of Public Policy. Retrieved 11 May 2026, from https://sa-policy-space.vercel.app/ideas/african-medicines-agency-treaty-ratification-and-sahpra-strengthening?snapshot=2026-05-11
Data as of 2026-05-11 · latest PMG meeting 2026-05-08
National Action Plan on Substandard and Falsified Medical Products: implement joint WHO-SAHPRA action plan (launched 30 September 2025); establish a rapid alert system linked to Interpol Project Pangea and the WHO Global Surveillance and Monitoring System
eCTD dossier standardisation: complete migration to ICH eCTD v4.0 submission standard; publish updated labelling requirements aligned with ICH E3/E6 guidelines; attract international pharmaceutical manufacturers to use SA as their African market gateway registration jurisdiction
NHI benefit package medicines registration priority lane: SAHPRA and the National Department of Health to jointly identify medicines proposed for the NHI benefit package and establish a dedicated fast-track review process with a 90-day target
18 months to full AMA reliance operationalisation and material backlog reduction (Q1 2026–Q2 2027)
SAHPRA annual budget R350 million (2025/26); backlog clearance requires an additional R80 million/year for temporary reviewer capacity (contract pharmacists and clinical evaluators); AMA reliance programme R25 million/year for technical assistance and capacity sharing with partner regulatory authorities
AMA Treaty ratified (complete). SAHPRA established under the South African Health Products Regulatory Authority Act 35 of 2015. No new primary legislation required. Regulatory amendments needed under the Medicines and Related Substances Act 101 of 1965: SAHPRA Regulations on fast-track registration lanes and WHO CRP implementation — published as Government Notice by the Minister of Health.
SAHPRA strengthening has strong cross-party support and strong international support (WHO, African Union, Bill and Melinda Gates Foundation). NHI political dynamics are more complex — SAHPRA's role in NHI benefit package design is contested by private sector interests, but the AMA reliance mechanism is operationally separate from NHI. Department of Health credibility post-COVID vaccine rollout (net positive despite distribution challenges) supports the reform agenda. Budget constraints are the main risk — SAHPRA is structurally under-resourced relative to the regulatory burden it carries.
Tanzania's TFDA became an AMA reliance pioneer: fast-tracked registration of over 200 medicines in 2023 using SAHPRA review packages, reducing average registration time from 24 months to 6 months for those products. Ghana FDA's WHO CRP implementation (2022): 93 essential medicines registered in 90 days, used as the WHO model for African regulatory capacity. Australia's TGA reliance on European EMA assessments (2016) reduced duplication effort by 60% while maintaining Australian-specific safety standards — the direct operational model for SAHPRA's AMA reference authority role.
TB Elimination National Acceleration Programme
Health · May 2023